Incanthera
WHAT WE DO

A revolutionary oncology company

Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.

View what we do
SOL

Our most advanced program

The Company’s current lead product and focus is Sol, which the Company acquired in September 2018. Sol is a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

Find out more about Sol

Investors

Regulatory News

Latest News & Media

Press Coverage
December 06th, 2021

Incanthera says talks started with 2 more companies for the commercial rights to Sol

Read more
Webinar
September 23rd, 2021

Watch the Life Sciences Investor Forum

Read more
News
December 06th, 2021

Interim results for the six months ended 30 September 2021

Read more
View All News And Media